Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11)

Medical and Pediatric Oncology

Volumn 41, Issue 1, 2003, Pages 78-80

  Palmer, Roger David ^a   Williams, Denise Mary ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Irinotecan (CPT11); Relapsed hepaloblastoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; RAZOXANE; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ABDOMINAL CRAMP; ADOLESCENT; ARTICLE; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HEMOPTYSIS; HEPATOBLASTOMA; HUMAN; LIVER RESECTION; LUNG LOBECTOMY; LUNG METASTASIS; MALE; NAUSEA; PRIORITY JOURNAL; VOMITING; CANCER STAGING; DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; METASTASIS; MULTIPLE CANCER; PATHOLOGY; TUMOR RECURRENCE;

ADOLESCENT; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY;

EID: 0037734135     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10300     Document Type: Article

References (12)

1. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma-results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1. Eur J Cancer 2000;36:1418-1425.
2. Quinn JJ, Altman AJ, Robinson HT, et al. Adriamycin and cisplatin for hepatoblastoma. Cancer 1985;56:1926-1929.
3. Ninane J, Perilongo G, Stalens JP, et al. Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: A SIOP Pilot Study. Med Pediatr Oncol 1991;19:199-203.
4. Houghton PJ, Cheshire PJ, Hallman JD, II, et al. Efficacy of topoisomerase I inhibitors, topotecan, and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenograft human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
5. Vassal G, Terrier-Lacomb M, Bissery M, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996;74:737-745.
6. Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997;3:423-431.
7. Vassal G, Borland I, Santos A, et al. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 1997;73:156-163.
8. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-1824.
9. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients. A Pediatric Oncology Group Study. Clin Cancer Res 2001;7:32-37.
10. Warmann SW, Fuchs J, Wilkens L, et al. Successful therapy of subcutaneusly growing human hepatoblastoma xenografts with topotecan. Med Pediatr Oncol 2001;37:449-454.
11. Ma MK, Zamboni WC, Radomski KM, et al. Pharmacokinetics of irinoteean and its metabolites SN-38 and APC in children with recurrent solid tumours after protracted low dose irinoteean. Clin Cancer Res 2000;6:813-819.
12. Cottu PH, Extra JM, Lerebows F, et al. Clinical activity spectrum of irinoteean [French]. Bulletin du Cancer 1998:21-25.